US › Healthcare

Biodesix Inc (BDSX)

US · Healthcare · Diagnostics & Research

$28.81+0.88%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$26.9M

Revenue YoY

+34.2%

Net profit

$-7.3M

EPS

$-0.71

EPS estimate

$-0.86

Net margin

-27.1%

EPS came in at -0.71 against a street estimate of -0.86 — a beat of 17.4%.

Key statistics

Market cap

$284.5M

Forward P/E

0.0

P/B

31.17

Book value

$0.87

EPS (TTM)

$-3.10

52-week high

$31.31

52-week low

$5.26

50-day MA

$23.56

200-day MA

$15.37

Beta

0.59

Analyst view

Analysts rate Biodesix Inc a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $34.00.

Shareholding

Insiders

40.13%

Institutions

41.41%

Largest institutional holders

Fund	Stake
AIGH Capital Management, LLC	6.43%
Soleus Capital Management, L.P.	5.55%
Telemark Asset Management, LLC	4.64%
Aberdeen Group PLC	3.68%
Vanguard Capital Management, LLC	2.42%
Essex Investment Management Company, LLC	2.29%
Opaleye Management Inc	1.71%
Marshall Wace Asset Management Ltd	1.34%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biodesix Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.